Isoniazid and Rifampin-Resistance Mutations Associated With Resistance to Second-Line Drugs and With Sputum Culture Conversion. (31st January 2020)

• Record Type: Journal Article
• Authors: Click, Eleanor S; Kurbatova, Ekaterina V; Alexander, Heather; Dalton, Tracy L; Chen, Michael P; Posey, James E; Ershova, Julia; Cegielski, J Peter
• Is Part Of: Journal of infectious diseases. Volume 221:Number 12(2020)
• Page Start: 2072
• Page End: 2082
• Publication Date: 2020-01-31
• Subjects: culture conversion -- drug resistance -- isoniazid -- rifampin -- second-line drugs tuberculosis; Communicable diseases -- Periodicals; Diseases -- Causes and theories of causation -- Periodicals; Medicine -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.9
• DOI: 10.1093/infdis/jiaa042
• Languages: English
• ISSNs: 0022-1899

Abstract

Abstract: Background: Mutations in the genes inhA, katG, and rpoB confer resistance to anti-tuberculosis (TB) drugs isoniazid and rifampin. We questioned whether specific mutations in these genes were associated with different clinical and microbiological characteristics. Methods: In a multicountry prospective cohort study of multidrug-resistant TB, we identified inhA, katG, and rpoB mutations in sputum isolates using the Hain MTBDR plus line probe assay. For specific mutations, we performed bivariate analysis to determine relative risk of baseline or acquired resistance to other TB drugs. We compared time to sputum culture conversion (TSCC) using Kaplan-Meier curves and stratified Cox regression. Results: In total, 447 participants enrolled from January 2005 to December 2008 from 7 countries were included. Relative to rpoB S531L, isolates with rpoB D516V had less cross-resistance to rifabutin, increased baseline resistance to other drugs, and increased acquired fluoroquinolone resistance. Relative to mutation of katG only, mutation of inhA promoter and katG was associated with baseline extensively drug resistant (XDR) TB, increased acquired fluoroquinolone resistance, and slower TSCC (125.5 vs 89.0 days). Conclusions: Specific mutations in inhA and katG are associated with differences in resistance to other drugs and TSCC. Molecular testing may make it possible to tailor treatment and assess additional drug resistance risk according to specific mutation profile. Abstract : Specific mutations in inhA, katG, and rpoB are associated with differences in resistance to other drugs and time-to-sputum-culture-conversion. Molecular testing may make it possible to tailor treatment and assess additional drug resistance risk according to specific mutation profile.